All licensed drugs/vaccines have to have (by law) a document called Summary of Product Characteristics (SPC or SmPC).
These documents have to contain all relevant data concerning efficacy (effectiveness) and safety, both from animal and human studies (the exact content is mandated by the governing body responsible for licensing in each region, so FDA in the US, EMEA in Europe).
They are also obligated, again legally, to disclose any information relating to experience or lack of experience in special populations, of which pregnant women are one.
This is what it says regarding use in pregnant women in the SPC for Celvapan (the unadjuvanted vaccine):
"There are currently no data available on the use of Celvapan in pregnancy. Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity.
Animal studies with Celvapan do not indicate reproductive toxicity.
The use of Celvapan may be considered during pregnancy if this is thought to be necessary, taking into account official recommendations.
Celvapan may be used in lactating women."
Essentially, there are no officially reported data with Celvapan in pregnant women, but data with similar unadjuvanted vaccines don't suggest any toxicity to the baby.
Now here is the equivalent text from the Pandemrix (adjuvanted) SPC:
"There are currently no data available on the use of Pandemrix in pregnancy. Data from pregnant women vaccinated with different inactivated non-adjuvanted seasonal vaccines do not suggest malformations or fetal or neonatal toxicity.
Animal studies with Pandemrix do not indicate reproductive toxicity.
The use of Pandemrix may be considered during pregnancy if this is thought to be necessary, taking into account official recommendations.
Pandemrix may be used in lactacting women."
It is exactly the same. The fact that the SPC of an adjuvanted vaccine can only refer to similar data with unadjuvanted vaccines proves that there is little/no relevant experience with adjuvanted vaccines in pregnant women, otherwise it would be cited here. Interestingly, the Pandemrix one says it was updated 20th Nov 09, so if there were any data in pregnant women, it would have been added then (and it wasn't).
This information alone is what has convinced me to push for Celvapan, since this (i.e. the unadjuvanted vaccine) is the closest they have to what has already been used with no ill effects in pregnant women.
Hope that makes sense. There is so much data flying around, but IMO, these documents are the definitive sources of what data are/are not available to support the use of these vaccines during pregnancy.
www.emea.europa.eu/humandocs/PDFs/EPAR/celvapan/spc/emea-spc-h982pu06en.pdf
emc.medicines.org.uk/medicine/22352/SPC/Pandemrix+suspension+and+emulsion+for+emulsion+for+injection /#PREGNANCY